Clinical trial NCT05043987: Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Official title: A Phase 1, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate Safety of CPO102, an Anti-claudin 18.2 Antibody-MMAE Drug Conjugate Administered Intravenously in Patients With Advanced Pancreatic and Gastric Cancers
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Pancreatic Cancer
Gastric Cancer
Keywords: Claudin 18.2 ADC
Phase 1
CPO102
Pancreatic Cancer
Gastric Cancer
Lead sponsor: Conjupro Biotherapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: CSPC Megalith Biopharmaceutical Co.,Ltd.
First posted: 2021-09-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available.

Detailed description: This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available. All patients must have failed standard first or later lines of systemic therapy.

The study design overview is presented below. The study will consist of 2 parts, Part A and Part B. Part A will explore once every 3 weeks (Q3W) dosing per standard 3+3 dose escalation design. Upon attaining a RP2D, Part B will commence in 2 groups, in approximately 15 patients with advanced pancreatic cancer and 15 patients with advanced gastric including gastric esophageal junction cancers. Part B will seek to confirm the RP2D and will also seek early signals of efficacy in the selected cancer patient populations.

Eligibility criteria: Inclusion Criteria:

Applicable to all patients in both Part A and Part B of the study:

* Pathological diagnosis (histological) of pancreatic or gastric including esophageal junction cancers.
* Patient must provide archived tissue block or formalin-fixed paraffin-embedded (FFPE) slides or fresh biopsy prior to start of treatment.
* Positive claudin 18.2 tumor expression defined as ≥50% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block.
* Adequate organ function.
* Life expectancy \>12 weeks.
* Age ≥18 years.
* ECOG performance status 0 or 1 at screening.
* Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent.
* Patients of reproductive potential: All female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before study entry.

Specific criteria for Part A:

* Disease progression or relapse following conventional chemotherapy:

  1. Pancreatic cancer
  2. Gastric cancer (including GEJ cancer)

Specific criteria for Part B:

* Measurable disease suitable for imaging and efficacy tracking as defined by RECIST 1.1
* Disease progression or relapse following conventional chemotherapy:

  1. Pancreatic cancer
  2. Gastric cancer (including GEJ cancer)

Exclusion Criteria:

1. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to baseline or to common terminology criteria for adverse events (CTCAE) grade ≤1, with the exception of alopecia, ≥grade 2 neuropathy, or to the levels dictated in the inclusion/exclusion criteria.
2. Patient has participated in any investigational research study and is being screened for participation within a period of 5 half-lives or 4 weeks, whichever is longer, of the last dose of the investigational therapy.
3. History of severe infusion reaction with monoclonal antibody treatment.
4. Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening.
5. HIV positive test within 8 weeks of screening.
6. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
7. Presence of other active cancers, or history of treatment for invasive cancer ≤3 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, noninvasive) are eligible, as are patients with history of nonmelanoma skin cancer.
8. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
9. Active central nervous system (CNS) disease involvement, defined by cerebrospinal fluid (CSF) cytology, magnetic resonance imaging (MRI) or computerized tomography (CT); patients with asymptomatic CNS metastases are eligible if participants have been clinically stable for at least 4 weeks prior to the first dose of study drug and do not require interventions such as surgery, radiation or any corticosteroid therapy for management of symptoms related to CNS disease.
10. Peripheral neuropathy Grades ≥ 2.
11. Active ocular surface disease at baseline (based on ophthalmic evaluation).
12. Pregnant or nursing (lactating) women.
13. Patients who received claudin 18.2 targeting agents previously.
14. Patients who have received or will receive coronavirus disease 2019 (COVID-19) vaccine within 72 hours prior to the first dose of study drug.
15. Prior radiotherapy

Primary outcomes:
measure: Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.
timeFrame: through study completion, an average of 3 year
Secondary outcomes:
measure: Number of participants with treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by relationship.
timeFrame: through study completion, an average of 3 year
measure: Number of participants with clinically significant changes in vital signs
timeFrame: through study completion, an average of 3 year
measure: Number of participants with clinically significant changes in clinical laboratory tests
timeFrame: through study completion, an average of 3 year
measure: CPO102 pharmacokinetics: Area under the concentration time curve over the dosing interval.
timeFrame: through study completion, an average of 3 year
measure: CPO102 pharmacokinetics: Maximum concentration of the drug (Cmax)
timeFrame: through study completion, an average of 3 year
measure: CPO102 pharmacokinetics: Time to maximum concentration (Tmax)
timeFrame: through study completion, an average of 3 year
measure: CPO102 pharmacokinetics: Elimination half-life (t1/2)
timeFrame: through study completion, an average of 3 year
measure: CPO102 pharmacokinetics: Clearance (CL)
timeFrame: through study completion, an average of 3 year
measure: CPO102 Objective response rate (ORR)
timeFrame: through study completion, an average of 3 year
measure: CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA)
timeFrame: through study completion, an average of 3 year
Other outcomes:
Locations:
Study officials:
affiliation: Conjupro Biotherapeutics, Inc.
name: Jiangfeng Su, MD, PhD
role: STUDY_DIRECTOR
References: